Table 1.
Baseline characteristics of the study patients (n = 37).
| UPN | Gender | Age at dia-gnosis, years | Year of dia-gnosis | Cancer type | Cancer predispo-sition syndrome | Event | Out-come | Follow-up (years) | Registration at LCR | Treating center |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 14 | 2000 | Hemangioendothelioma of atrium (L) | NS | Progress | Died | 1.1 | Registered | VUHSK |
| 2 | M | 10 | 2000 | Pheochromocytoma (L) | VHL | CR | Alive | 19.3 | Registered | VUHSK |
| 3 | F | 11 | 2001 | Lung cancer (L) | NS | CR | Alive | 18.1 | Registered | VUHSK |
| 4 | F | 2 | 2002 | Liver angiosarcoma (L) | NS | Progress | Died | 1.3 | Registered | VUHSK |
| 5 | M | 16 | 2005 | Adrenocortical carcinoma (A) | NS | Progress | Died | 0.6 | Registered | VUHSK |
| 6 | F | 17 | 2005 | Uterine adenosarcoma (L) | NS | 2ndCa | Died | 9.6 | Unregistered | LUHSKC |
| 7 | F | 16 | 2005 | Renal carcinoma (L) | NS | CR | Alive | 11.1 | Registered | VUHSK |
| 8 | F | 7 | 2005 | Adrenocortical carcinoma (L) | NS | Progress | Died | 2.2 | Registered | VUHSK |
| 9 | M | 4 | 2005 | Intestinal hemangioendotelioma (L) | NS | Progress | Died | 0.6 | Registered | VUHSK |
| 10 | F | 8 | 2005 | Medullary thyroid carcinoma (L) | MEN2 | Relapse | Died | 11.8 | Unregistered | LUHSKC |
| 11 | F | 17 | 2006 | Renal carcinoma (L) | NS | CR | Alive | 13.6 | Registered | LUHSKC |
| 12 | F | 17 | 2006 | Medullary thyroid carcinoma (L) | NS | Progress | Died | 7.0 | Registered | LUHSKC |
| 13 | F | 17 | 2006 | Pancreatic papillary carcinoma | NS | CR | Alive | 13.5 | Registered | VUHSK |
| 14 | M | 11 | 2006 | Intestinal neuroendocrine tumor (L) | NS | Progress | Died | 0.7 | Registered | VUHSK |
| 15 | F | 15 | 2006 | Renal carcinoma (L) | NS | CR | Alive | 13.1 | Registered | LUHSKC |
| 16 | F | 0 | 2006 | Adrenocortical carcinoma (A) | NS | Progress | Died | 0.1 | Registered | LUHSKC |
| 17 | F | 17 | 2007 | Adrenocortical carcinoma (L) | NS | Relapse | Died | 8.9 | Registered | LUHSKC |
| 18 | F | 1 | 2007 | Kaposi-like hemangioendothelioma (L) | NS | CR | Alive | 12.1 | Registered | VUHSK |
| 19 | F | 15 | 2009 | Ovarian carcinoma (L) | NS | CR | Alive | 10.2 | Registered | LUHSKC |
| 20 | M | 6 | 2010 | Renal carcinoma (L) | NS | CR | Alive | 9.9 | Unregistered | LUHSKC |
| 21 | M | 15 | 2010 | Follicular dendritic sarcoma (L) | NS | Progress | Died | 0.4 | Registered | VUHSK |
| 22 | F | 16 | 2010 | Ovarian carcinoma (A) | NS | Progress | Died | 0.1 | Registered | LUHSKC |
| 23 | F | 10 | 2010 | Carcinoma of upper lip (L) | NS | Relapse | Alive | 7.0 | Registered | VUHSK |
| 24 | M | 14 | 2010 | Adenocarcinoma of stomach (L) | NS | CR | Alive | 9.2 | Registered | VUHSK |
| 25 | F | 0 | 2010 | Adrenocortical carcinoma (L) | Li Fraumeni | 2ndCa | Died | 6.2 | Registered | VUHSK |
| 26 | F | 14 | 2011 | Adrenocortical carcinoma (A) | NS | Relapse | Died | 2.6 | Registered | VUHSK |
| 27 | M | 15 | 2012 | Colorectal adenocarcinoma (L) | NS | Progress | Died | 0.3 | Registered | LUHSKC |
| 28 | M | 12 | 2012 | Adenocarcinoma of stomach (L) | NS | Progress | Died | 0.1 | Registered | LUHSKC |
| 29 | F | 15 | 2012 | Salivary gland carcinoma (L) | NS | CR | Alive | 7.2 | Unregistered | LUHSKC |
| 30 | M | 17 | 2013 | Pheochromocytoma (L) | VHL | CR | Alive | 6.9 | Registered | LUHSKC |
| 31 | M | 0 | 2013 | Rhabdoid tumor1 (L) | NS | TRM | Died | 0.3 | Registered | VUHSK |
| 32 | M | 8 | 2013 | Retroperitoneal DSRCT (A) | NS | Relapse | Died | 2.1 | Registered | VUHSK |
| 33 | M | 14 | 2013 | Skin melanoma (L) | NS | CR | Alive | 6.7 | Registered | VUHSK |
| 34 | F | 9 | 2014 | Medullary thyroid carcinoma (L) | MEN2 | CR | Alive | 5.9 | Unregistered | LUHSKC |
| 35 | M | 3 | 2014 | Rhabdoid tumor2 (A) | NS | CR | Alive | 5.7 | Registered | VUHSK |
| 36 | M | 0 | 2014 | Rhabdoid tumor3 (L) | NS | Progress | Died | 0.6 | Registered | VUHSK |
| 37 | M | 12 | 2015 | Salivary gland carcinoma (L) | NS | CR | Alive | 4.1 | Unregistered | LUHSKC |
2ndCa, the second cancer; A, advanced stage at diagnosis; CR, complete remission; DSRCT, desmoplastic small round cell tumor; F, female; L, local disease at diagnosis; LUHSKC, Lithuanian University of Health Sciences Kaunas Clinics; M, male; MEN2, multiple endocrine neoplasia type 2; NS, not specified; TRM, treatment related mortality; UPN, unique patient number in the study; VHL, von Hippel Lindau syndrome; VUHSK, Vilnius University Hospital Santaros Klinikos.
1Rhabdoid tumor of the thoracic wall.
2Rhabdoid tumor of multiple supradiaphragmatic lymph nodes and lung metastases.
3Rhabdoid tumor of right axillar soft tissue.